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Introduction: Compared to Alzheimer’s disease (AD), dementia with Lewy bodies (DLB) is usually associated
with a more complex clinical picture and higher burden of care. Yet, few investigations have been performed
on comorbidities and risk factors of DLB. Therefore, we aimed to compare clinical risk factors and comorbidity
profile in DLB and AD patients using two nationwide registries.
Methods: This is a linkage study between the Swedish dementia registry (SveDem) and the Swedish National
Patient Registry conducted on 634 subjects with DLB and 9161 individuals with AD registered during the years
2007–2012. Comorbidity profile has been coded according to the International Classification of Diseases version
10 (ICD 10) in addition to the date of each event. The main chapters of the ICD-10, the Charlson score of
comorbidities and a selected number of neuropsychiatric diseases were compared between the DLB and AD
groups. Comorbidity was registered before and after the dementia diagnosis.
Results: “Mental and behavioral disorders”, “diseases of the nervous system”, “diseases of the eye and adnexa”, diseases
of the “circulatory”, “respiratory”, and “genitourinary” systems, “diseases of the skin and subcutaneous tissue” and
“diseases of the musculoskeletal system and connective tissue” occurred more frequently in the DLB group after
multivariate adjustment. Depression [adjusted OR = 2.12 (95%CI 1.49 to 3.03)] and migraine [adjusted OR = 3.65
(95%CI 1.48 to 9.0)] were more commonly recorded before the diagnosis of dementia in the DLB group. Following
dementia diagnosis, ischemic stroke [adjusted OR = 1.89 (95%CI 1.21 to 2.96)] was more likely to happen among
the DLB patients compared to the AD population.
Conclusions: Our study indicated a worse comorbidity profile in DLB patients with higher occurrence of
depression, stroke and migraine compared with the AD group. Deeper knowledge about the underlying
mechanisms of these associations is needed to explore possible reasons for the different pattern of
comorbidity profile in DLB compared to AD and their prognostic significance.* Correspondence: dorota.religa@ki.se
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Dementia with Lewy bodies (DLB) is the second most
common type of degenerative dementia after Alzheimer’s
disease (AD) [1]. Compared with AD, DLB is associated
with poorer prognosis, shorter time to nursing home
admission, higher care burden and higher healthcare costs
[2-4]. However, cognitive and functional decline do not
seem to differ between these two groups [5]. In addition
to a more complex clinical picture of DLB that is charac-
terized by visual hallucinations, motoric symptoms, sleep
disorders and autonomic dysfunction, comorbidities may
be crucial predictors of worse outcomes in DLB pa-
tients. Comorbid diseases significantly increase utilization
of healthcare resources [2], predict key outcomes of acute
hospital care in older people [6] and are associated with a
higher risk of death after dementia diagnosis [7].
Little attention has been paid to research on comor-
bidities and risk factors of DLB. Previous studies showed
that occurrence of depression [8,9] and anxiety [10] is
higher in DLB patients when compared with AD. De-
pression has been suggested as a risk factor for DLB [9]
and was more likely to persist over time in DLB subjects
compared with AD patients [11]. History of stroke and
anxiety has been reported to occur more often in DLB
patients than in healthy controls, but not in comparison
with AD patients [9].
Correct assessment of risk factors and comorbidities is
a central part of clinical management of DLB patients.
Furthermore, understanding them may provide new
insights into the underlying pathophysiology of DLB. In
this study, capitalizing on two nationwide registries, we
compared clinical risk factors and comorbidity profiles
for AD and DLB in 9,795 subjects, including 634 patients
with DLB. To the authors’ best knowledge this is one of
the largest published DLB cohorts.
Methods
This study was performed by linking the Swedish
Dementia Registry (SveDem) and the Swedish National
Patient Registry. The personal identity number was used
as the unique identifier for merging the two databases.
Patients were followed-up until 31 December 2012.
Swedish Dementia Registry
SveDem is a nationwide registry that includes newly
diagnosed dementia patients from Sweden [12]. SveDem
is a web-based quality registry, initiated in 2007, to
improve the quality of diagnostics work-up, treatment and
care of dementia across the country [13]. The majority of
patients are registered through specialist care units (mem-
ory clinics) and the type of dementia is recorded as early-
onset AD, late-onset AD, mixed AD, vascular dementia,
DLB, frontotemporal dementia, Parkinson’s disease with
dementia, unspecified dementia or others.At the end of 2012, 58 specialist units (93% of all in
Sweden) and 659 primary care centers (60% of all in
Sweden) were affiliated with SveDem. Using an estimated
incidence rate of 20,000 patients that develop dementia in
Sweden each year [14], the approximate coverage of inci-
dent dementia cases in SveDem in 2012 was 36%. How-
ever, the study population represents a census of all newly
diagnosed dementia patients because all of those who
referred to the registered centers were recruited.
This study population comprised only two subgroups,
634 individuals with DLB (DLB group) and 9,161 cases
with AD (AD group), recruited during the years 2007 to
2012. Dementia was diagnosed according to the Inter-
national Classification of Diseases (ICD) version 10 criteria
[15]. In addition, McKeith criteria were used to diagnose
DLB [16].
Information about age, sex, living conditions, medi-
cation profile, diagnosis of DLB and AD (ICD version 10
codes of G31.8 for DLB and G30.0 and G30.1 for AD),
baseline Mini-Mental State Examination (MMSE) score
[17] and date of referral for dementia work-up were
obtained from the SveDem records.
Swedish National Patient Registry
The Swedish National Patient Registry is administered
by the Swedish National Board of Health and Welfare,
which covers inpatient care in Sweden to 1987 [18]. The
doctor responsible for the patient determines the diag-
noses in the registry based on clinical evaluations and
laboratory assessments on that particular occasion of in-
hospital care. Diagnoses were coded using the latest
version of the ICD according to the year of registration.
At the time of discharge, the physician registers a main
diagnosis and one or more secondary diagnoses if ap-
plicable for each patient. A similar procedure is also per-
formed through all outpatient clinics and afterwards. The
diagnostic codes are sent by the hospitals and outpatient
clinics to the National Board of Health and Welfare. Later,
one main diagnosis and up to seven secondary diagnoses
are registered together with demographics and admi-
nistrative information such as hospital, clinic, dates of
admission and discharge, surgical procedures and patient
characteristics including age, sex and place of residence.
Data obtained from 2000 to 2012 were used for this study.
Comorbidity profile
In addition to the main chapters of the ICD version 10,
another comparison was performed based on the comor-
bidity scoring of the ICD version 10 codes recommended
by the Royal College of Surgeons called the Charlson
Score [19]. The total Charlson score of comorbidities was
calculated by counting the number of comorbidity cate-
gories without any preassigned weights [20]. Data on a se-
lected list of neuropsychiatric diseases were also extracted
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version 10 codes as follows: depression (F32, F33), anxiety
(F40, F41), behavioral disorders (F07, F10, F11, F12, F13,
F14, F15, F16, F17, F18, F19, F53, F54, F59, F66, F68, F69,
F98, R46), bipolar affective disorder (F31), sleep disorder
(F51, G47), syncope (R55), ischemic stroke (I63, I64, I67,
I69), cerebral hemorrhage (I60, I61, I62), epilepsy (G40),
migraine (G43) and other types of headache (G44, R51).
The time of registration was used to check whether the
disease occurred before or after dementia diagnosis as well
as to calculate the time intervals between the dates.
Since no information is available on the exact time
when the symptoms started, we used the date of regis-
tration as the initial time point for dementia and the
comorbidities. Therefore, if the date of registration for
any of the comorbidities has been recorded prior to the
date of registration in SveDem, we considered that co-
morbidity has occurred before dementia, and vice versa.
Statistical analysis
The mean (standard deviation (SD)) and frequency per-
centage (%) were reported to describe quantitative and
categorical variables. For univariate comparisons, the
chi-square statistic and Fisher’s exact test were used to
compare the relative frequency of nominal variables
(that is, sex, comorbidities) between the two study groups
where appropriate. To compare the mean value of quan-
titative variables between the DLB and AD groups, either
an independent-sample t test or a Mann–Whitney U
test were used for normally or skewed distributions,
respectively.
Further multivariate analysis was performed to adjust
for the confounding effect of the baseline differences in
age and sex between the DLB and AD groups. For this
purpose, a binary logistic regression model was applied
to evaluate the differences observed in the prevalence of
different comorbidities between the DLB and AD groups
adjusted for the baseline confounders. Afterwards, the
adjusted odds ratio (OR) and its corresponding 95% con-
fidence interval (CI) for each comorbidity were calcu-
lated. For the comorbidities that occurred before the
date of referral for dementia, type of dementia (DLB vs.
AD) was considered the dependent variable. If the co-
morbid event happened after dementia diagnosis, the
comorbidity was defined as the dependent variable and
the type of dementia as a predictor in the multivariate
model. In all analytical procedures, two-tailed P < 0.05
was considered to show statistically significant difference.
Data were analyzed using SPSS software version 22 (IBM
Co., Chicago, IL USA).
Ethical issues
The regional Ethical Committee of Stockholm approved
data collection (Drn. 2013/147-31/2), as well as the mergingand the analytical procedures performed in this study.
The patients were informed orally and in writing about
SveDem and could decline participation. Data were coded
and anonymized before statistical analysis.Results
Baseline characteristics
A total number of 634 individuals with DLB and 9,161 AD
patients were recruited. The DLB group consisted of 382
(60.3%) males and 252 (39.7%) females with a mean age of
76.5 (SD = 7.1) years. The AD group comprised 3,188
(34.8%) males and 5,973 (65.2%) females with a mean age
of 77.6 (SD = 8.3) years at the time of dementia diagnosis.
Results of the Pearson chi-square test and the independ-
ent-samples t test revealed that there were significantly
more males (P < 0.001) and fewer old patients (P < 0.001)
in the DLB group. Other baseline, demographic and
medication characteristics of the two study groups are
presented and compared in Table 1. The mean of the
baseline MMSE score was quite similar in the DLB (21.4
(SD = 5.0)) and AD (21.5 (SD = 5.0)) groups (P = 0.593).
However, in the DLB group the proportion of patients in
nursing homes was larger than that in the AD group
(11.8% vs. 5.6%, P < 0.001).
DLB patients were under treatment with a significantly
higher number of medications (4.7 (SD = 3.0)) compared
with the AD group (3.7 (SD = 2.9)). A multivariate Poisson
regression model showed that DLB patients received a
higher number of drugs (B = 0.268 (95% CI = 0.230 to
0.307), P < 0.001) after adjustment for sex and age. While
a similar proportion of patients were treated with cho-
linesterase inhibitors in both the DLB (73.6%) and AD
(72.7%) groups (P = 0.272), N-methyl D-aspartate anta-
gonists (15.0% vs. 9.9%), antidepressants (34.8% vs. 26.3%),
antipsychotics (16.3% vs. 4.9%) and anxiolytics (13.3% vs.
8.2%) were significantly more often prescribed among the
DLB group.International Classification of Diseases version 10 chapters
Table 2 summarizes the comorbidity profile of the DLB
and AD patients based on the chapters of the ICD ver-
sion 10 coding system. ‘Mental and behavioral disorders’
(66.1%) and ‘diseases of the eye and adnexa’ (57.9%) were
the most common categories recorded for the DLB
group apart from the ‘diseases of the nervous system’;
while among the AD patients ‘diseases of the eye and
adnexa’ (47.9%), ‘diseases of the musculoskeletal system
and connective tissue’ (40.7%) and ‘diseases of the circu-
latory system’ (40.3%) were most commonly recorded as
comorbid conditions. ‘Mental and behavioral disorders’,
‘diseases of the nervous system’, ‘diseases of the eye and
adnexa’, diseases of the ‘circulatory’, ‘respiratory’, ‘digestive’
and ‘genitourinary’ systems and the ‘diseases of the skin
Table 1 Baseline, diagnostic and medication characteristics of the two study groups: cases suffering from dementia
with Lewy bodies versus Alzheimer’s disease patients
Characteristic
Dementia with Lewy bodies Alzheimer’s disease
P value
(n = 634) (n = 9,161)
Gender
<0.001aFemale 252 (39.7%) 5973 (65.2%)
Male 382 (60.3%) 3188 (34.8%)
Age (years) 76.5 (7.1) 77.6 (8.3) <0.001b
MMSE score 21.4 (5.0) 21.5 (5.0) 0.593b
Body mass index (kg/m2) 24.4 (4.1) 24.3 (4.1) 0.565b
Living place
<0.001aOwn house 559 (88.2%) 8627 (94.4%)
Nursing home 75 (11.8%) 512 (5.6%)
Co-resident
<0.001a
Yes 218 (36.0%) 3879 (44.0%)
No 387 (64.0%) 4938 (56.0%)
Medication (at the time of diagnosis)
Cholinesterase inhibitors 465 (73.6%) 6598 (72.7%) 0.272a
NMDA antagonist 95 (15.0%) 895 (9.9%) <0.001a
Antidepressants 220 (34.8%) 2382 (26.3%) <0.001a
Antipsychotics 103 (16.3%) 447 (4.9%) <0.001a
Anxiolytics 84 (13.3%) 747 (8.2%) <0.001a
Hypnotics 106 (16.8%) 1292 (14.2%) 0.065a
Cardiovascular drugs 365 (57.8%) 4825 (53.2%) 0.054a
Total number of drugs 4.7 (3.0) 3.7 (2.9) <0.001b
Data presented as number (%) or mean (standard deviation). Statistically significant differences (P < 0.05) in bold. MMSE, Mini-Mental State Examination; NMDA,
N-methyl D-aspartate. aPearson chi-square statistic. bIndependent-sample t test.
Fereshtehnejad et al. Alzheimer's Research & Therapy 2014, 6:65 Page 4 of 14
http://alzres.com/content/6/5/65and subcutaneous tissue’ occurred more commonly in the
DLB group based on the univariate comparisons.
As shown in Table 2, all univariate significant differ-
ences remained statistically significant after multivariate
adjustment except for the ‘diseases of the digestive sys-
tem’. Moreover, DLB patients suffered more from the
‘diseases of the musculoskeletal system and connective tis-
sue’ after adjustment for age and sex (adjusted OR = 1.19
(95% CI = 1.01 to 1.41)). The greatest between-group
differences in the ICD version 10 disease categories were
observed in ‘mental and behavioral disorders’ (66.1% vs.
38.7%, adjusted OR = 3.14 (95% CI = 2.63 to 3.75)),
‘diseases of the nervous system’ (88.0% vs. 71.0%, adjusted
OR = 2.78 (95% CI = 2.15 to 3.58)) and ‘diseases of the
eye and adnexa’ (57.9% vs. 47.9%, adjusted OR = 1.69
(95% CI = 1.42 to 2.01)), all of which were more common
in the DLB group.
Further subgroup analysis was performed to assess
how patients’ gender, level of cognition and living place
might affect the differences in the comorbidity profile
between the DLB and AD groups. As summarized in
Table 3, some comorbidity categories such as ‘mental and
behavioral disorders’ and ‘diseases of the nervous system’were significantly more common in the DLB group among
all of the subgroups regarding gender, cognition and living
place (all P < 0.05). On the other hand, ‘diseases of the
circulatory system’ was significantly more prevalent in the
DLB patients who were female (46.8% vs. 38.6%, P = 0.009),
had MMSE < 22 (49.6% vs. 39.1%, P = 0.001) and live in
their own house (46.3% vs. 40.2%, P = 0.005).
Although ‘diseases of the respiratory system’ was more
commonly recorded in the DLB patients with both
MMSE ≥ 22 (P = 0.043) and MMSE < 22 (P = 0.018), with
regard to gender and living place the difference was sig-
nificant only among the males (27.7% vs. 20.5%, P = 0.001)
and those who live in their own houses (22.9% vs. 18.0%,
P = 0.004). Furthermore, ‘diseases of the digestive system’
(38.9% vs. 30.3%, P = 0.003) and ‘diseases of the muscu-
loskeletal system and connective tissue’ (45.6% vs. 38.5%,
P = 0.022) were significantly higher in the DLB group
compared with the AD group only among the subgroup
with MMSE < 22 at the time of diagnosis.
Charlson comorbidity scoring
Comorbidity profiles of the DLB and AD patients using
the Royal College of Surgeons Charlson categorization
Table 2 Comorbidity profile of the patients with dementia with Lewy bodies versus Alzheimer’s disease patients based on the chapters of the International
Statistical Classification of Diseases and Related Health Problems, 10th Revision
Chapter Blocks Title
DLB AD Unadjusted P valuea Adjusted P valueb
(n = 634) (n = 9,161) OR (95% CI) OR (95% CI)
I A00 to B99 Certain infectious and parasitic diseases 87 (13.7) 1,064 (11.6) 1.21 (0.96 to 1.53) 0.111 1.25 (0.98 to 1.59) 0.069
II C00 to D48 Neoplasms 203 (32.0) 2,733 (29.8) 1.11 (0.93 to 1.32) 0.245 1.06 (0.88 to 1.27) 0.541
III D50 to D89 Diseases of the blood and blood-forming
organs and certain disorders involving
the immune mechanism
29 (4.6) 433 (4.7) 0.97 (0.66 to 1.42) 0.861 1.01 (0.68 to 1.49) 0.976
IV E00 to E90 Endocrine, nutritional and metabolic diseases 79 (12.5) 1,088 (11.9) 1.06 (0.83 to 1.35) 0.661 1.16 (0.90 to 1.49) 0.239
V F00 to F99 Mental and behavioral disorders 419 (66.1) 3,543 (38.7) 3.09 (2.61 to 3.66) <0.001 3.14 (2.63 to 3.75) <0.001
VI G00 to G99 Diseases of the nervous system 558 (88.0) 6,508 (71.0) 2.99 (2.34 to 3.82) <0.001 2.78 (2.15 to 3.58) <0.001
VII H00 to H59 Diseases of the eye and adnexa 367 (57.9) 4,390 (47.9) 1.49 (1.27 to 1.76) <0.001 1.69 (1.42 to 2.01) <0.001
VIII H60 to H95 Diseases of the ear and mastoid process 96 (15.1) 1,462 (16.0) 0.94 (0.75 to 1.18) 0.586 0.97 (0.77 to 1.22) 0.810
IX I00 to I99 Diseases of the circulatory system 293 (46.2) 3,693 (40.3) 1.27 (1.08 to 1.49) 0.003 1.29 (1.08 to 1.52) 0.004
X J00 to J99 Diseases of the respiratory system 146 (23.0) 1,663 (18.2) 1.35 (1.11 to 1.63) 0.002 1.30 (1.06 to 1.59) 0.010
XI K00 to K93 Diseases of the digestive system 237 (37.4) 2,966 (32.4) 1.25 (1.05 to 1.47) 0.009 1.17 (0.98 to 1.39) 0.082
XII L00 to L99 Diseases of the skin and subcutaneous
tissue
155 (24.4) 1,918 (20.9) 1.22 (1.01 to 1.47) 0.036 1.27 (1.05 to 1.54) 0.016
XIII M00 to M99 Diseases of the musculoskeletal system
and connective tissue
273 (43.1) 3,732 (40.7) 1.10 (0.93 to 1.29) 0.250 1.19 (1.01 to 1.41) 0.040
XIV N00 to N99 Diseases of the genitourinary system 233 (36.8) 2,984 (32.6) 1.20 (1.02 to 1.42) 0.030 1.24 (1.04 to 1.47) 0.015
XV O00 to O99 Pregnancy, childbirth and the puerperium 1 (0.2) 2 (0.0) – – – –
XVI P00 to P96 Certain conditions originating in the
perinatal period
0 0 – – – –
XVII Q00 to Q99 Congenital malformations, deformations
and chromosomal abnormalities
5 (0.8) 57 (0.6) 1.27 (0.51 to 3.18) 0.609 1.55 (0.61 to 3.98) 0.358
XVIII R00 to R99 Symptoms, signs and abnormal clinical
and laboratory findings, not elsewhere
classified
460 (72.6) 5,896 (64.4) 1.46 (1.22 to 1.75) <0.001 1.44 (1.19 to 1.73) <0.001
XIX S00 to T98 Injury, poisoning and certain other
consequences of external causes
369 (58.2) 4,679 (51.1) 1.33 (1.13 to 1.57) 0.001 1.54 (1.30 to 1.83) <0.001
XX V01 to Y98 External causes of morbidity and
mortality
0 1 (0.0) – – – –
XXI Z00 to Z99 Factors influencing health status and
contact with health services
523 (82.5) 6,718 (73.3) 1.71 (1.39 to 2.11) <0.001 1.73 (1.39 to 2.16) <0.001
Adjustment is made for age, sex, and Mini-Mental State Examination score. The AD group is considered the reference group. Statistically significant ORs (P < 0.05) in bold. AD, Alzheimer’s disease; CI, confidence interval;
















Table 3 Comorbidity profile of patients with dementia with Lewy bodies (n = 634) versus Alzheimer’s disease patients
(n = 9,161) within different subgroups regarding gender, cognitive level at the time of diagnosis and living place using















Male 14.9 12.5 0.183 MMSE≥ 22 16.3 11.2 0.005 Own house 14.3 11.4 0.038
Female 11.9 11.1 0.703 MMSE < 22 11.9 12.2 0.855 Nursing home 9.3 15.0 0.188
Neoplasms
Male 35.6 33.8 0.494 MMSE≥ 22 32.8 31.6 0.652 Own house 32.4 30.1 0.259
Female 26.6 27.7 0.701 MMSE < 22 31.9 27.9 0.169 Nursing home 29.3 25.4 0.467




Male 5.2 4.8 0.687 MMSE≥ 22 3.6 4.5 0.447 Own house 4.7 4.6 0.967
Female 3.6 4.7 0.403 MMSE < 22 5.9 4.8 0.414 Nursing home 4.0 6.8 0.457
Endocrine, nutritional and
metabolic diseases
Male 12.8 10.9 0.262 MMSE≥ 22 10.5 11.7 0.526 Own house 12.3 11.8 0.700
Female 11.9 12.4 0.819 MMSE < 22 15.9 11.8 0.046 Nursing home 13.3 13.5 0.973
Mental and behavioral
disorders
Male 67.3 37.4 <0.001 MMSE≥ 22 65.7 40.8 <0.001 Own house 65.5 38.8 <0.001
Female 64.3 39.3 <0.001 MMSE < 22 66.7 36.0 <0.001 Nursing home 70.7 36.5 <0.001
Diseases of the nervous
system
Male 91.4 72.8 <0.001 MMSE≥ 22 89.5 75.5 <0.001 Own house 88.7 72.2 <0.001
Female 82.9 70.1 <0.001 MMSE < 22 86.3 66.8 <0.001 Nursing home 82.7 52.3 <0.001
Diseases of the eye and
adnexa
Male 56.5 44.2 <0.001 MMSE≥ 22 60.2 49.0 <0.001 Own house 58.3 47.7 <0.001
Female 59.9 49.9 0.002 MMSE < 22 55.6 47.0 0.007 Nursing home 54.7 52.0 0.660
Diseases of the ear and
mastoid process
Male 15.4 17.2 0.383 MMSE≥ 22 17.5 17.1 0.857 Own house 15.7 16.2 0.790
Female 14.7 15.3 0.794 MMSE < 22 14.1 14.6 0.819 Nursing home 10.7 12.9 0.588
Diseases of the circulatory
system
Male 45.8 43.5 0.391 MMSE≥ 22 43.7 40.8 0.296 Own house 46.3 40.2 0.005
Female 46.8 38.6 0.009 MMSE < 22 49.6 39.1 0.001 Nursing home 45.3 41.2 0.499
Diseases of the respiratory
system
Male 27.7 20.5 0.001 MMSE≥ 22 22.0 17.6 0.043 Own house 22.9 18.0 0.004
Female 15.9 16.9 0.677 MMSE < 22 24.4 18.6 0.018 Nursing home 24.0 20.1 0.438
Diseases of the digestive
system
Male 41.6 37.0 0.079 MMSE≥ 22 36.7 34.3 0.357 Own house 37.7 32.7 0.013
Female 31.0 29.9 0.721 MMSE < 22 38.9 30.3 0.003 Nursing home 34.7 27.9 0.229
Diseases of the skin and
subcutaneous tissue
Male 24.3 20.2 0.057 MMSE≥ 22 25.3 22.5 0.230 Own house 24.7 21.1 0.043
Female 24.6 21.3 0.217 MMSE < 22 24.1 19.3 0.056 Nursing home 22.7 18.6 0.397
Diseases of the musculoskeletal
system and connective tissue
Male 39.8 36.1 0.157 MMSE≥ 22 41.3 42.9 0.555 Own house 42.9 41.0 0.371
Female 48.0 43.2 0.132 MMSE < 22 45.6 38.5 0.022 Nursing home 44.0 37.5 0.280
Diseases of the genitourinary
system
Male 36.4 32.1 0.093 MMSE≥ 22 38.0 33.6 0.108 Own house 38.3 32.6 0.005
Female 37.3 32.8 0.138 MMSE < 22 35.6 31.1 0.132 Nursing home 25.3 32.6 0.205
Pregnancy, childbirth and
the puerperium
Male – – – MMSE≥ 22 0.3 0 0.062 Own house 0.2 0 0.061
Female 0.4 0 0.117 MMSE < 22 0 0.1 1 Nursing home 0 0.4 1
Certain conditions originating
in the perinatal period
Male 0 0 – MMSE≥ 22 0 0 – Own house 0 0 –




Male 1.0 0.6 0.300 MMSE≥ 22 0.9 0.6 0.464 Own house 0.7 0.5 0.545
Female 0.4 0.6 1 MMSE < 22 0.7 0.4 0.349 Nursing home 1.3 2.1 1
Symptoms, signs and abnormal
clinical and laboratory findings,
not elsewhere classified
Male 72.8 66.9 0.020 MMSE≥ 22 74.1 67.2 0.010 Own house 72.3 64.5 <0.001
Female 72.2 63.0 0.003 MMSE < 22 71.5 61.3 0.001 Nursing home 74.7 62.7 0.043
Injury, poisoning and certain
other consequences of
external causes
Male 50.8 45.1 0.034 MMSE≥ 22 59.6 49.2 <0.001 Own house 58.3 50.2 <0.001
Female 69.4 54.3 <0.001 MMSE < 22 56.7 53.5 0.312 Nursing home 57.3 64.8 0.206
Fereshtehnejad et al. Alzheimer's Research & Therapy 2014, 6:65 Page 6 of 14
http://alzres.com/content/6/5/65
Table 3 Comorbidity profile of patients with dementia with Lewy bodies (n = 634) versus Alzheimer’s disease patients
(n = 9,161) within different subgroups regarding gender, cognitive level at the time of diagnosis and living place using
the chapters of the International Statistical Classification of Diseases and Related Health Problems, 10th Revision
(Continued)
External causes of morbidity
and mortality
Male 0 0 – MMSE≥ 22 0 0 – Own house 0 0 –
Female 0 0 – MMSE < 22 0 0 – Nursing home 0 0 –
Factors influencing health
status and contact with
health services
Male 81.4 73.0 <0.001 MMSE≥ 22 84.3 76.8 0.001 Own house 83.2 73.8 <0.001
Female 84.1 73.5 <0.001 MMSE < 22 81.1 69.8 <0.001 Nursing home 77.3 65.8 0.047
Statistically significant differences (P < 0.05) in bold. Univariate comparisons were performed using either the chi-square or Fisher’s exact test wherever appropriate.
AD, Alzheimer’s disease; DLB, dementia with Lewy bodies; MMSE, Mini-Mental State Examination.
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Cerebrovascular diseases were more common in the
DLB group after adjustment for age and sex (16.2% vs.
10.0%, adjusted OR = 1.74 (95% CI = 1.38 to 2.19)). As
illustrated in Figure 1, 12.7% of the AD patients had
a zero score according to the Charlson scoring of the
comorbidities, while only 3.3% of the DLB patients
showed this condition. The proportion of individuals
with one, two and three or more comorbidity categor-
ies of Charlson scoring was higher in the DLB group
(P < 0.001). Moreover, DLB patients had a significantly
higher mean for the total Charlson score (1.52 (SD = 0.85)
vs. 1.33 (SD = 0.89)). This difference remained signifi-
cant even after multivariate adjustment (OR = 1.22 (95%
CI = 1.12 to 1.33)).Table 4 Comorbidity profile of the patients with dementia wi
on the Royal College of Surgeons Charlson Score indicating I
for 14 disease categories
Disease category
DLB AD Un
(n = 634) (n = 9,161) OR
Myocardial infarction 34 (5.4) 532 (5.8) 0.92
Congestive cardiac failure 38 (6.0) 458 (5.0) 1.21
Peripheral vascular disease 15 (2.4) 271 (3.0) 0.79
Cerebrovascular disease 103 (16.2) 912 (10.0) 1.75 (
Chronic pulmonary disease 27 (4.3) 480 (5.2) 0.80
Rheumatological disease 12 (1.9) 286 (3.1) 0.60
Liver disease 4 (0.6) 48 (0.5) 1.20
Diabetes mellitus 26 (4.1) 481 (5.3) 0.77
Hemiplegia or paraplegia 0 19 (0.2)
Renal disease 11 (1.7) 98 (1.1) 1.63
Any malignancy 94 (14.8) 1283 (14.0) 1.07
Metastatic solid tumor 2 (0.3) 74 (0.8) 0.39
AIDS/HIV infection 0 1 (0.0)
Total Charlson score 1.52 (0.85) 1.33 (0.89) 1.25 (
Data presented as mean (standard deviation). Adjustment is made for age, sex, and M
group. The dementia category of the original Charlson scoring is not reported here be
significant ORs (P < 0.05) in bold. AD, Alzheimer’s disease; CI, confidence interval; DLB,
regression model.Neuropsychiatric comorbidities
Considering the date of registration in SveDem and the
Swedish National Patient Registry, occurrence of the
selected neuropsychiatric comorbidities was determined
as either before or after dementia diagnosis. As presented
in Table 5, depression was the most common neuro-
psychiatric comorbidity before the diagnosis of dementia
in both groups (6.0% in DLB and 3.0% in AD). Among
strokes, cerebral infarction was more common in the DLB
group than in the AD group, while the frequency of cere-
bral hemorrhages did not differ between the AD and DLB
groups. According to univariate comparisons (Table 5),
depression (P < 0.001), behavioral disorders (P = 0.012),
stroke (P = 0.002) and migraine (P = 0.028) were all more
frequent in individuals with DLB compared with the ADth Lewy bodies versus Alzheimer’s disease patients based
nternational Classification of Disease, 10th revision codes
adjusted P valuea Adjusted P valueb
(95% CI) OR (95% CI)
(0.64 to 1.31) 0.643 0.85 (0.59 to 1.22) 0.372
(0.86 to 1.70) 0.270 1.21 (0.85 to 1.73) 0.282
(0.47 to 1.34) 0.392 0.77 (0.45 to 1.31) 0.335
1.40 to 2.19) <0.001 1.74 (1.38 to 2.19) <0.001
(0.54 to 1.20) 0.281 0.88 (0.59 to 1.31) 0.525
(0.33 to 1.07) 0.081 0.64 (0.35 to 1.19) 0.160
(0.43 to 3.35) 0.578 1.13 (0.40 to 3.19) 0.818
(0.52 to 1.15) 0.206 0.73 (0.48 to 1.11) 0.145
– 0.631 – 0.998
(0.87 to 3.06) 0.123 1.57 (0.83 to 2.97) 0.167
(0.85 to 1.34) 0.565 0.96 (0.75 to 1.21) 0.707
(0.09 to 1.59) 0.239 0.42 (0.10 to 1.74) 0.235
– – – –
1.15 to 1.36) <0.001 1.22 (1.12 to 1.33) <0.001
ini-Mental State Examination score. The AD group is considered the reference
cause the whole study population is dementia patients in our study. Statistically
dementia with Lewy bodies; OR, odds ratio. aChi-square statistics. bBinary logistic
Figure 1 Frequency of dementia with Lewy bodies and Alzheimer’s disease in patients with different number of comorbidities.
Frequency of dementia with Lewy bodies (DLB, n = 634) and Alzheimer’s disease (AD, n = 9,161) in patients with different number of
comorbidities based on the categories of the Royal College of Surgeons Charlson Score identified on the International Classification of Disease,
10th revision codes.
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significantly different between the two groups (3.2% in
DLB and 3.4% in AD, OR = 0.92 (95% CI = 0.58 to 1.45),
P = 0.713).
Figure 2 illustrates the forest plots of adjusted OR for
each neuropsychiatric comorbidity in DLB with AD as
the reference group. With respect to the timing of the
events, depression (adjusted OR = 2.12 (95% CI = 1.49 to
3.03)) and migraine (adjusted OR = 3.65 (95% CI = 1.48
to 9.0)) were more commonly recorded before the diag-
nosis of dementia in the DLB group (Figure 2B). As
shown in Figure 2C, ischemic stroke (adjusted OR = 1.89
(95% CI = 1.21 to 2.96)) was the only significant comorbid
condition that was more likely to happen among the DLB
patients compared with the AD population after the onset
of dementia.
Further subgroup analysis was performed regarding
gender, cognitive level and living place. As summarized
in Table 6, depression and stroke were more common in
the DLB group compared with AD patients among both
males and females (all P < 0.05), whereas the higher
prevalence of anxiety in DLB patients was statistically
significant only among the males (3.4% vs. 1.8%, P = 0.031).
With respect to level of cognition, depression, stroke and
migraine were significantly more common in DLB patients
compared with the AD group only among those with
MMSE < 22 (all P < 0.05). Depression, sleep disorders and
stroke were more commonly occurred in the DLB patients
compared with the AD group among those who were
living in their own house (all P < 0.05), while migraine
was more prevalent in DLB patients who lived in nursing
homes (2.7% vs. 0.2%, P = 0.045).Discussion
In this study we investigated selected risk factors and
comorbidities in patients suffering from DLB in com-
parison with AD. There were more males in the DLB
group, which is in line with previous studies [21]. At the
time when dementia diagnosis was set, DLB patients
were younger, and, despite similar level of cognitive im-
pairment, lived more frequently in nursing homes and
received more psychiatric medication and a higher total
number of drugs. This indicates a worse health profile at
the time when dementia was diagnosed and suggests
that DLB patients may have been affected by a larger
number of diseases before they developed dementia
compared with the AD subjects. Patients with DLB were
more frequently affected with depression, stroke and
cerebrovascular infarctions and migraine.
Medication
There were some interesting differences in the use of
medication. Cholinesterase inhibitors were used in the
majority of DLB and AD patients. Although these drugs
are indicated for AD and Parkinson’s disease with demen-
tia, but not formally for DLB, there is good evidence that
they are also useful in DLB [22,23]. Memantine was pre-
scribed for 15% of DLB patients and 10% of AD patients,
although the evidence is less conclusive for DLB. However,
there are some indications that memantine may in fact be
useful also for DLB [24], including meta-analysis data [23].
Depression
Depression was more frequent in both men and women
in the DLB group compared with AD, particularly in
Table 5 Occurrence and timing for different neuropsychiatric comorbidities in patients with dementia with Lewy
bodies versus Alzheimer’s disease patients
Comorbidity
Dementia with Lewy bodies Alzheimer’s disease P valuea
(n = 634) (n = 9,161)
Depression <0.001
None 587 (92.7) 8,736 (95.5)
Before dementia diagnosis 38 (6.0) 277 (3.0)
After dementia diagnosis 8 (1.3) 130 (1.4)
Anxiety 0.508
None 612 (96.7) 8,905 (97.4)
Before dementia diagnosis 16 (2.5) 172 (1.9)
After dementia diagnosis 5 (0.8) 66 (0.7)
Behavioral disorders 0.012
None 612 (96.7) 8,964 (98.0)
Before dementia diagnosis 9 (1.4) 107 (1.2)
After dementia diagnosis 12 (1.9) 72 (0.8)
Bipolar affective disorder 0.258
None 628 (99.2) 9,100 (99.5)
Before dementia diagnosis 5 (0.8) 36 (0.4)
After dementia diagnosis 0 7 (0.1)
Sleep disorders 0.093
None 616 (97.3) 9,001 (98.4)
Before dementia diagnosis 14 (2.2) 116 (1.3)
After dementia diagnosis 3 (0.5) 26 (0.3)
Syncope 0.472
None 587 (92.7) 8,486 (92.8)
Before dementia diagnosis 35 (5.5) 443 (4.8)
After dementia diagnosis 11 (1.7) 214 (2.3)
Stroke 0.002
None 580 (91.6) 8,665 (94.8)
Before dementia diagnosis 28 (4.4) 277 (3.0)
After dementia diagnosis 25 (3.9) 201 (2.2)
Cerebral hemorrhage 0.709
None 623 (98.4) 9,015 (98.6)
Before dementia diagnosis 6 (0.9) 62 (0.7)
After dementia diagnosis 4 (0.6) 66 (0.7)
Epilepsy 0.291
None 622 (98.3) 9,022 (98.7)
Before dementia diagnosis 8 (1.3) 66 (0.7)
After dementia diagnosis 3 (0.4) 55 (0.6)
Migraine 0.028
None 627 (99.1) 9,113 (99.7)
Before dementia diagnosis 6 (0.9) 28 (0.3)
After dementia diagnosis 0 2 (0.0)
Data presented as number (%). Statistically significant differences (P < 0.05) in bold. aPearson chi-square statistics.
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Figure 2 Forest plot for odds ratios of the selected list of
neuropsychiatric comorbidities for dementia with Lewy bodies
compared with Alzheimer’s disease as the reference group in
different three conditions. (A) Overall assessment (regardless of
the timing). (B) Comorbidities recorded prior to the diagnosis of
dementia as a risk factor for type of dementia (DLB vs. AD). (C) Type
of dementia (DLB vs. AD) as a risk factor for comorbidities occurred
after the diagnosis of dementia. AD, Alzheimer’s disease; CI, confidence
interval; DLB, dementia with Lewy bodies.
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dementia was diagnosed. Depression is a common fea-
ture of DLB [11], especially in its early stages. Several
hypotheses have linked depression to the etiology and
pathophysiology of dementia, depression may be a risk
factor for DLB [9]. DLB has also been associated with a
higher risk of depression [25]. The etiology of depression
is probably multifactorial and the relation to dementia is
complex. In our study, depression was significantly more
often diagnosed in DLB patients before they were diag-
nosed with dementia. After the dementia diagnosis was
set, depression occurrence did not differ between the DLB
and AD patients.
It is a matter of dispute whether depression is a risk
factor or a prodromal stage of DLB. Nonmotor symptoms
and widespread brain pathological changes are believed to
occur in DLB before dementia onset [26], so depression
may be a sign of underlying pathological changes that are
already present in DLB subjects. It would be of interest to
investigate whether prevention or treatment of depression
could decrease the incidence of DLB or postpone the
development of dementia.
Migraine
In our study, migraine was more common in the DLB
group before dementia was diagnosed. Furthermore, it oc-
curred more frequently in DLB patients that had a lower
MMSE score at the time of diagnosis. Migraine was shown
as a risk factor for developing dementia [27] and associ-
ated with smaller brain tissue volumes [28]. Recently,
headache has been suggested as a risk factor for the devel-
opment of vascular dementia in a prospective population-
based study [29]. However, there are no previous studies
investigating migraine in DLB patients. Conditions that
are common in DLB patients and subjects suffering from
migraine include complex visual hallucination [30] and
disorders in olfactory perception [31]. Even though their
etiology seems different, further research on these two dis-
orders could provide valuable insights into the relation-
ship between DLB and migraine.
Stroke
Strokes were found to be more common for both men
and women in the DLB group compared with the AD
group, especially in subjects with lower MMSE scores.
The occurrence of cerebrovascular infarctions but not
cerebral hemorrhages after dementia diagnosis was sig-
nificantly higher in the DLB group compared with
AD patients. This relationship was not significant before
dementia was diagnosed. This finding is surprising as
strokes are common predictors for AD [32]. The differ-
ence in use of antipsychotics may be an explanation.
Studies on cerebrovascular pathology in DLB patients
are not numerous and provide contradictory results. In a
Table 6 Frequency of different neuropsychiatric comorbidities in patients with dementia with Lewy bodies (n = 634)
versus Alzheimer’s disease patients (n = 9,161) within different subgroups regarding gender, cognitive level at the
time of diagnosis and living place using the chapters of the International Statistical Classification of Diseases and
Related Health Problems, 10th Revision
Title Gender DLB (%) AD (%) P value Cognition DLB (%) AD (%) P value Living place DLB (%) AD (%) P value
Depression
Male 6.3 3.8 0.020 MMSE≥ 22 6.3 5.2 0.350 Own house 7.0 4.5 0.006
Female 8.7 4.8 0.005 MMSE < 22 7.4 3.5 0.001 Nursing home 9.3 3.9 0.068
Anxiety
Male 3.4 1.8 0.031 MMSE≥ 22 3.3 2.7 0.464 Own house 3.2 2.6 0.372
Female 3.2 3.0 0.901 MMSE < 22 3.3 2.7 0.528 Nursing home 4.0 2.8 0.469
Behavioral disorders
Male 3.4 2.6 0.381 MMSE≥ 22 2.4 1.9 0.471 Own house 2.9 1.8 0.079
Female 3.2 1.6 0.071 MMSE < 22 3.7 2.0 0.062 Nursing home 6.7 4.1 0.362
Bipolar affective
disorders
Male 0.5 0.5 0.702 MMSE≥ 22 0.6 0.5 0.689 Own house 0.9 0.4 0.185
Female 1.2 0.5 0.129 MMSE < 22 1.1 0.4 0.105 Nursing home 0 1.0 1
Sleep disorders
Male 3.9 2.5 0.094 MMSE≥ 22 2.7 2.0 0.339 Own house 2.7 1.6 0.040
Female 0.8 1.1 1 MMSE < 22 2.2 1.1 0.124 Nursing home 2.7 1.4 0.325
Syncope
Male 7.1 6.7 0.789 MMSE≥ 22 6.9 7.4 0.782 Own house 7.5 7.2 0.740
Female 7.5 7.4 0.950 MMSE < 22 7.8 6.9 0.579 Nursing home 5.3 7.7 0.471
Stroke
Male 8.7 6.0 0.043 MMSE≥ 22 6.9 5.3 0.193 Own house 8.4 5.1 0.001
Female 7.9 4.8 0.025 MMSE < 22 9.3 5.0 0.002 Nursing home 8.0 7.1 0.772
Cerebral hemorrhage
Male 1.8 1.6 0.732 MMSE≥ 22 1.2 1.2 0.547 Own house 1.8 1.4 0.410
Female 1.2 1.3 1 MMSE < 22 1.9 1.7 0.807 Nursing home 0 1.8 0.613
Epilepsy
Male 1.6 1.5 0.958 MMSE≥ 22 1.2 1.3 1 Own house 1.8 1.3 0.287
Female 2.0 1.2 0.242 MMSE < 22 2.2 1.2 0.165 Nursing home 1.3 2.4 1
Migraine
Male 0.5 0.2 0.249 MMSE≥ 22 0.9 0.4 0.165 Own house 0.7 0.3 0.138
Female 1.6 0.4 0.580 MMSE < 22 1.1 0.2 0.034 Nursing home 2.7 0.2 0.045
Univariate comparisons were performed using either the chi-square or Fisher’s exact test wherever appropriate. Statistically significant differences (P < 0.05) in
bold. AD, Alzheimer’s disease; DLB, dementia with Lewy bodies; MMSE, Mini-Mental State Examination.
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no lesions of ischemic strokes were present in these sub-
jects. The study suggested that the diagnosis of DLB had
a protective effect against stroke [33]. Another study
suggested that DLB patients with advanced typical Lewy
body pathology were less likely to have history of stroke
and cerebrovascular diseases [34]. This study revealed
that infarcts, atherosclerosis and small vessel disease
were inversely correlated to the extent of the DLB path-
ology. Nevertheless, cerebral amyloid angiopathy was
associated with the grade of DLB pathology. A neuropa-
thological case report revealed severe cerebral amyloid
angiopathy in the presence of DLB pathology [35]. How-
ever, it can be argued that cerebral amyloid angiopathy
is not related to DLB, but rather is a sign of pathological
aging and concomitant AD [36,37].
Even though the reasons are not clear, our study –
strengthened by a large sample size – revealed a signifi-
cantly frequent occurrence of stroke, specifically cerebral
infarctions in DLB patients. More research is thus crucial
to further elucidate this association. It can be speculated
that the use of antipsychotics may have contributed to
the development of strokes [38]. It is of interest that aconsiderable proportion of DLB patients were treated
with antipsychotic medication before they were diag-
nosed with dementia (16%). This could be due to the
clinical presentation of DLB, in which, in contrast to
AD, frequent visual hallucinations are common early in
the disease process.
Underlying psychiatric disorders may also be con-
founders [39] and lead to need for antipsychotics. It has
been shown that antipsychotic treatment in dementia is
associated with worse outcomes such as shorter time to
nursing home admission, cerebrovascular events and mor-
tality in older people [4,40-42]. The Swedish guidelines for
the treatment of neuropsychiatric symptoms in dementia
therefore state that antipsychotics should be used very re-
strictively and only for psychotic symptoms or aggression
that causes suffering or potential danger to the patient or
others [20]. However, they are often prescribed to older
people with dementia [43,44], particularly in the nursing
home setting [45,46].
Cardiovascular comorbidities are frequent in all demen-
tia disorders [47,48] and belong to commonly reported
causes of death [49]. In our study they have been found
more common in the DLB group compared with AD,
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house and have a lower cognitive status at the beginning
of the diagnostic process. A recent nationwide study in
Sweden revealed that 60% of DLB patients were treated
with cardiovascular medication, but the use of these drugs
was lower in this group compared with AD [47]. However,
this difference may be attributed to the fear of side effects
in DLB patients; for example, side effects due to autono-
mic dysfunction. AD patients present the lowest mortality
rate compared with other dementia disorders [7] and are
therefore considered the healthiest group of dementia
patients [50], even though there are some contradictory
reports [51,52]. Investigating comorbidities in patients
with dementia can provide with valuable insights into de-
mentia disorders and contribute to better understanding
of their pathophysiology.
Limitations and strengths
One may criticize that the study is limited by the val-
idity of diagnoses. However, the validity of the Swedish
National Patient Registry has been shown to be high for
many diagnoses [53]. Nevertheless, the underestimation of
comorbidities is inevitable since the Swedish National
Patient Registry is based on outpatient or inpatient refer-
rals and those with mild symptoms who did not seek med-
ical help are not recorded. The validity of the data in
SveDem has been assessed, especially in memory clinics.
The data registered in memory clinics in a random sample
of patients were in good agreement with medical records
in a validation process [54]. Moreover, although we con-
sidered timing for the events, the probability of reverse
causation is not completely omitted.
The validity of the diagnosis of dementia disorders has
not been examined. It is necessary to acknowledge that
the way of diagnosing both dementia types in SveDem
reflects clinical practice in Sweden, and biomarkers such
as dopamine transporter single-photon emission computed
tomography is not available at all centers. Symptoms of
DLB and AD overlap, which leads to difficulties in the
diagnostic process. Autopsy diagnosis is currently not
available but many patients are followed longitudinally,
which probably improves diagnostic accuracy. Linking
SveDem to autopsy records in future could help assess
the accuracy of the clinical diagnoses.
Our study benefits from one of the largest samples of
DLB patients in the world. Most of the previous studies
have focused either on a single or a small number of
comorbidities, while we compared the entire comorbidity
profile. Using the exact date of registration for each co-
morbidity and dementia, we had access to the consecutive
timing of the events in order to determine whether
comorbidities occurred either before or after dementia
diagnosis. Both SveDem and the Swedish National Patient
Registry have just a minute proportion of missing values.The personal registration number makes it possible to
follow each individual over time and to connect corre-
sponding information from different registries in Sweden.
The number of hospital stays with missing personal regis-
tration numbers in the inpatient registry was only 0.6% in
2006 [53].
Conclusions
Our study indicated a worse comorbidity profile in DLB
patients, with a higher prevalence of depression, stroke
and migraine, compared with the AD population. Dee-
per knowledge about these differences among the DLB
and AD groups is needed. Future studies could explore
whether the presented associations are due to different
mechanisms of these disorders as well as studying their
influence on diagnostics and care.
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